Question Bank › Proof-point cadence

Proof-point cadence

Proof-point cadence: the last promised marker just landed, and the next one is already on the clock

Calls Tested
345
Answered YES
24
Hit Rate
7%
rare by design

Precipio, Inc. (PRPO) — this company's answers

NO on the Q3 2018 call 2018-11-19 D
The model's full reasoning — Q3 2018 call → NO我们根据提供的财报电话会议记录来判断。管理层是否将公司进展呈现为“实时、可核查的证明点序列”，并且同时包含两个要素：(1) 刚刚交付的标记；(2) 下一个标记已命名且临近。 分析记录内容： - 管理层提到了ICP产品线的扩展（从1个检测到5个面板覆盖17个外显子），这是产品开发进展。 - 与Perkin Elmer的合作协议宣布，这是商业化的里程碑。 - 病理服务收入增长50%，预计2019年中期达到每季度100万美元以上。 - IV-Cell和HemeScreen技术推出，HemeScreen刚推出两周已收到订单。 - 实验室内部扩展分子检测能力，减少外包。 关于“刚刚交付的标记”：例如，ICP产品线扩展、Perkin Elmer合作、HemeScreen推出等，这些是具体完成的步骤。 关于“下一个标记已命名且临近”：管理层提到2019年ICP收入预计几百万美元，病理服务收入目标，HemeScreen收入目标等。但需要看是否有具体时间锚定的下一步。例如，病理服务“by the middle of 2019”达到每季度100万美元，这是具体时间。HemeScreen“2019年收入超过100万美元”。ICP与Perkin Elmer合作预计2019年收入。这些是近期的目标。 但关键是要看管理层是否将进展呈现为“实时序列”，即刚刚完成一个检查点，下一个检查点已在计时。管理层确实在描述多个项目，但似乎没有明确说“我们刚刚完成了X，下一步是Y，Y将在Z时间完成”这样的连贯序列。不过，从整体看，管理层在描述多个并行项目，每个都有近期目标。 然而，问题要求“ONE phenomenon”即一个连贯的执行序列。这里似乎有多个序列（ICP、病理、HemeScreen等），但每个都有刚完成的和即将到来的。例如，ICP：刚推出5个面板，下一步是与Perkin合作扩大市场，2019年收入目标。病理：刚增长50%，下一步是达到每季度100万美元。HemeScreen：刚推出，下一步是2019年收入100万美元。 但问题强调“the same forward path”，即同一个路径上的连续步骤。这里可能不是单一序列，而是多个。但也许可以视为公司整体发展路径。 另外，注意问题中的排除条件：如果只是报告完成的成就而没有具体近期下一步，则NO；如果只是承诺未来里程碑而没有最近完成的检查点，则NO；如果只是财务结果，则NO；如果步骤是常规业务，则NO；如果下一步模糊、无日期、遥远或依赖融资等，则NO。 这里，管理层确实报告了具体完成的步骤（如产品扩展、合作、新测试推出），也给出了具体时间的目标（如2019年中期病理收入、2019年ICP收入等）。但需要检查这些下一步是否“锚定在近期（大约一年内）”，是的，都是2019年。而且管理层说“in motion”或“already being executed”，例如HemeScreen已开始商业化。 但有一个问题：这些下一步是否足够具体？例如，ICP收入“several hundreds to several million dollars”范围较宽，但时间明确。病理收入目标明确。HemeScreen收入目标明确。 另外，管理层是否将进展呈现为“驱动公司方向”的序列？是的，管理层在描述这些进展如何推动公司。 然而，注意问题要求“ONE coherent posture”，即一个连贯的姿态。这里管理层似乎有多个项目，但整体上是在描述公司多个方面的进展，每个都有刚完成和即将到来的。这可以视为一个整体执行序列。 但更严格地看，问题要求“the last checkpoint just cleared, the next checkpoint already on the clock”，即一个明确的序列。这里可能没有明确说“我们之前承诺了X，现在完成了X，接下来是Y”。但管理层在描述中隐含了这种进展。 例如，对于ICP，管理层说“Only a year ago we launched our first ICP test... Today, we have 5 panels... This product line will continue to expand throughout 2019”，这暗示了持续扩展。但“continue to expand”是模糊的，没有具体下一步。 对于病理，管理层说“revenues from pathology services growing close to 50% from the previous quarter”和“expect a continued rapid growth...

← Back to the full PRPO analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management present the company's progress as a LIVE, CHECKABLE SEQUENCE OF PROOF POINTS — with BOTH of the following present in management's own words as one coherent posture? (1) A MARKER JUST DELIVERED. Management reports that a specific, concrete operational step it had previously set out to accomplish has JUST been completed or reached in the recent period — something real and verifiable that happened (for example: a facility, line, or site brought online; a product, program, or service launched or shipped; a certification, approval, qualification, or acceptance obtained; a first delivery, first production, first customer, or go-live achieved; a ramp, rollout, conversion, or expansion reaching a defined stage; an integration, build, or transition completed). Management should treat this as a checkpoint passed on a path it had already described or committed to — not merely a good financial result, and not routine activity every quarter contains. (2) THE NEXT MARKER IS NAMED AND NEAR. Management also identifies the NEXT concrete step on that same forward path and anchors it in the near term (roughly within the coming year) with at least approximate timing — what specifically is supposed to happen next and when — presented as scheduled, in motion, or already being executed rather than as an aspiration, and specific enough that an observer could later tell whether it happened. The essence is ONE phenomenon, in whatever form fits the industry: a company moving through an execution sequence in real time — the last checkpoint just cleared, the next checkpoint already on the clock — with management inviting investors to track it step by step, and treating this progression (rather than general market conditions) as what is driving where the company is headed. Answer NO if the call reports only completed accomplishments with no specific near-term next step attached to the same path. NO if management only promises future milestones without any recently completed checkpoint behind them. NO if the only 'delivery' is beating financial guidance or reporting strong numbers, with no operational checkpoint passed. NO if the completed and upcoming steps are routine business-as-usual for this company (ordinary seasonal openings, standard product refreshes, normal maintenance) that management does not present as advancing the company's trajectory. NO if the next step is vague, undated, distant, or contingent on financing, approvals, or decisions not yet in hand. NO if management is chiefly explaining delays, misses, or resets of previously promised milestones. NO if the sequence is assembled only in an analyst's question or summary that management does not itself adopt. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
CMPS COMPASS Pathways plc Q3 2023 2023-11-04 F
VRE Veris Residential, Inc. Q4 2022 2023-02-22 D
ADPT Adaptive Biotechnologies Corporation Q4 2022 2023-02-14 C+
HIW Highwoods Properties, Inc. Q4 2022 2023-02-08 B
TCBI Texas Capital Bancshares, Inc. Q2 2021 2021-07-21 F
CUBI Customers Bancorp, Inc. Q3 2018 2018-10-26 C+
AU AngloGold Ashanti's Q2 2018 2018-08-20 B
XOM Exxon Mobil Corporation Q2 2018 2018-07-27 C
MKC McCormick & Company, Incorporated Q2 2018 2018-06-28 C+
CLMT Calumet Specialty Products Partners, L.P Q1 2018 2018-05-16 C+
ATI Allegheny Technologies Incorporated Q1 2018 2018-04-24 B
SCVL Shoe Carnival, Inc. Q4 2017 2018-03-27 C+
UPLD Upland Software, Inc. Q4 2017 2018-03-08 C+
ITCI Intra-Cellular Therapies, Inc. Q4 2017 2018-03-01 D
INSM Insmed Incorporated Q4 2017 2018-02-23 B
AOSL Alpha and Omega Semiconductor Limited Q2 2018 2018-02-07 B
SBSI Southside Bancshares, Inc. Q4 2017 2018-02-06 A
CPK Chesapeake Utilities Corporation Q3 2017 2017-11-10 A
HOLX Hologic, Inc. Q4 2017 2017-11-08 D
IBTX Independent Bank Group, Inc. Q3 2017 2017-10-24 A
MXL MaxLinear, Inc. Q2 2017 2017-08-08 C+
LIND Lindblad Expeditions Holdings, Inc. Q2 2017 2017-08-06 C
BP BP p.l.c. Q4 2016 2017-02-07 B+
RCL Royal Caribbean Cruises Ltd. Q1 2016 2016-04-29 C+

How the model reasoned

XOM · Q2 2018 → YESThe question is whether management presents the company's progress as a LIVE, CHECKABLE SEQUENCE OF PROOF POINTS with both a marker just delivered and the next marker named and near. YES Management presents a live, checkable sequence of proof points. In Neil Chapman's remarks, he explicitly notes that the Coral Floating LNG project is "progressing on schedule" and that "fabrication of the hull is expected to start in the third quarter of this year" — a concrete, near-term operational checkpoint 3–4 months away. Immediately prior, he states that "earlier this month, we announced that the development plan for the first phase has been submitted," treating that submission as the just-completed marker on the same path. He anchors the next step as "targeting final investment decision in 2019" with 2024 first LNG, presented as scheduled and already in motion rather than aspirational. This forms one coherent posture: the company is executing a verifiable execution sequence on the Mozambique LNG opportunity, with the development-plan submission just cleared and FID locked for 2019. Other examples (Baytown ethane cracker operations begun yesterday; 50 new Permian wells brought to sales in the quarter) exist, but the Mozambique LNG thread satisfies both required elements on a single forward path. No other elements (financial beats, routine maintenance, or analyst questions) are used to construct the sequence.
MKC · Q2 2018 → YESThe question is whether management presents the company's progress as a LIVE, CHECKABLE SEQUENCE OF PROOF POINTS with both a marker just delivered and the next marker named and near. YES The transcript shows management framing the Frank's and French's integration as a completed checkpoint ("With the acquisition and integration complete"), then immediately naming and anchoring the next concrete steps on the same path — such as launching the first dedicated mustard campaign in the U.S. (kicked off this week during the call) and 2018 U.S. national TV advertising for Frank's in the second half — as scheduled, in-motion activities that will drive further growth. This is presented as one coherent execution sequence rather than isolated results. Other elements like distribution gains and summer grilling promotions are tied directly to this progression. No routine or vague items qualify; 2018 advertising and marketing acceleration are explicitly tied to the post-integration trajectory.
CMPS · Q3 2023 → YESThe question is whether management presents the company's progress as a LIVE, CHECKABLE SEQUENCE OF PROOF POINTS with both a marker just delivered and the next marker named and near. YES The transcript shows management framing progress as a live execution sequence: the open-label PTSD Phase II study has just reached full recruitment (a concrete checkpoint passed), and they explicitly name the next marker — top-line readout this year — as the immediate follow-on step already in motion and scheduled within the coming months. This is presented as part of the same forward trajectory they are tracking, alongside the TRD Phase III where site initiations (3/4 of COMP005) are described as continuing to advance toward the summer 2024 readout.

More from the question bank

Scarcity premium: the thing the company sellLocus of control flipSomeone else already paid for the growthBetting on one customer's rampCorrecting the record with current factsCheck it yourselvesAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.